A 20-unit Botox treatment sells for $300. The vial cost $7 per unit wholesale. Your client just paid for a 6-session laser package up front, and only two of those sessions will happen this quarter. Your medical director's monthly retainer is fixed regardless of how many patients walked through the door. And the GLP-1 weight loss program you launched last spring now produces more revenue than every facial in the studio combined.
Welcome to medspa accounting—where high-margin injectables, deferred-revenue packages, capital-intensive lasers, and corporate-practice-of-medicine rules all collide in the same chart of accounts. The clinics that book this correctly run gross margins north of 70%. The ones that don't end up writing off "discounts" that were really revenue, paying tax on package money they haven't earned, and discovering at sale time that their financials don't survive a buyer's quality of earnings review.
This guide walks through the bookkeeping mechanics aesthetic clinic owners and their accountants need to get right.
Injectable COGS: Track Per-Unit, Not Per-Vial
The single most common mistake on a medspa P&L is expensing Botox, Dysport, Xeomin, Juvederm, Restylane, and Sculptra at purchase rather than at use. That treatment makes inventory disappear from the balance sheet, inflates COGS in the month you buy, and crushes COGS in the month you sell. Margins look chaotic, and you can't tell whether your injector is dosing efficiently or overusing product.
The right approach is straightforward:
- Capitalize at purchase. Every vial, syringe, and bottle goes onto the balance sheet as inventory at landed cost (invoice + shipping + any state pharmaceutical handling fee).
- Relieve to COGS per unit used. Botox typically arrives in 100-unit and 200-unit vials. A 20-unit forehead treatment relieves 20 units of inventory at the weighted-average unit cost. Fillers sell by the 1.0 mL syringe—relieve the full syringe even if a portion is wasted (it's still your cost).
- Track waste separately. Many practices reconstitute Botox and use partial vials across patients in a single day. Record actual product used per patient on the treatment record, then book the unused remainder of a reconstituted vial as Waste/Spoilage Expense, not COGS. Buyers in due diligence look for this split because high waste indicates poor injector training or appointment scheduling.
Industry benchmarks suggest aesthetic-treatment COGS should run 25–35% of service revenue, putting gross margin at 65–75%. If your reported COGS is bouncing between 10% and 60% month to month, the underlying issue is almost always inventory accounting—not pricing.
Cost Allocation Across Patients From a Single Vial
When a 100-unit Botox vial costs $480 at landed cost, your per-unit COGS is $4.80. A patient receiving 40 units carries $192 of COGS. A patient receiving 10 units carries $48. The remaining 50 units stay on the balance sheet until used or discarded. This per-unit allocation is what your point-of-sale or EMR system should be calculating automatically; if it isn't, your month-end close becomes a manual reconciliation nightmare.
Service Revenue Lines That Actually Mean Something
A flat "Service Revenue" account is useless for an aesthetic practice. The cost structures behind each treatment line are too different to make sense of a single number. Break revenue into at least these categories:
- Neuromodulators (Botox, Dysport, Xeomin, Daxxify, Jeuveau)
- Dermal fillers (HA fillers, biostimulators like Sculptra and Radiesse)
- Laser and energy-based services (IPL, laser hair removal, CO2, RF microneedling, body contouring like CoolSculpting, Emsculpt)
- Skincare services (facials, chemical peels, hydrafacials)
- IV therapy and vitamin injections
- Weight management / GLP-1 programs
- Retail product sales (separately, because sales tax treatment differs)
Each of these has its own COGS profile. Injectables are 25–35% COGS. Energy-based device services are 5–15% (consumable tips and gel only). Retail product sales run 40–55% COGS. Mixing them gives you a meaningless blended margin.
Prepaid Packages and Memberships: ASC 606 Deferred Revenue
When a client buys a "Package of 6 laser hair removal sessions" for $1,800 up front, you have not earned $1,800 of revenue. You have a contract liability—deferred revenue—and you recognize $300 of revenue each time a session is performed. This is straight ASC 606 Step 5: revenue is recognized as performance obligations are satisfied.
The journal entry at sale:
Dr. Cash $1,800
Cr. Deferred Revenue – Laser Packages $1,800The journal entry per session redeemed:
Dr. Deferred Revenue – Laser Packages $300
Cr. Service Revenue – Laser $300The same applies to memberships ("$199/month gets you one Hydrafacial plus 10% off"), gift cards, and prepaid annual programs. Until the service is delivered, the money is a liability.
Breakage: Revenue From Unused Sessions
Aesthetic clinics consistently experience significant breakage—clients who buy 6-session packages and never finish, gift cards that expire, memberships that lapse with unused entitlements. Typical industry breakage runs 15–25% on multi-session laser packages, 20–35% on facial packages, and 25–40% on annual membership perks.
Under ASC 606, if you can reasonably estimate breakage and you do not expect a refund obligation, you can recognize breakage revenue proportionally to redemptions rather than waiting for expiration. If a 6-session package has an expected 20% breakage rate, then for every session redeemed you recognize 1/6 of the package price as service revenue plus a pro-rata share of the breakage amount.
For most clinics it's simpler to take the conservative path: do not recognize breakage until the package expires or the client's right is extinguished. Either policy is acceptable—what's not acceptable is recognizing all the cash on sale and then quietly "writing off" the unused balance as a discount when the package expires. That overstates current revenue and understates future revenue.
Capitalize Lasers and Devices, Use Section 179 Strategically
A new aesthetic laser commonly costs $80,000–$250,000. CoolSculpting systems, fractional CO2 lasers, picosecond tattoo removal devices, and high-end RF microneedling platforms are major capital purchases. Two things matter for bookkeeping:
Capitalization, Not Expensing
The device itself is a fixed asset depreciated over its useful life—generally 5 to 7 years under MACRS for medical equipment. Capitalize the device, installation, shipping, and required training that's bundled with the purchase. Replacement handpieces, treatment tips, and disposable cartridges are not capitalized—those are consumables that hit COGS as used.
Section 179 and Bonus Depreciation
For tax purposes, Section 179 lets you immediately expense qualifying equipment up to a generous annual limit (currently $2.5 million in 2025, indexed). 100% bonus depreciation also remains available on qualifying property placed in service during the year. Used together, a $150,000 laser purchased and placed in service before year-end can be fully written off in the year of purchase—even if you financed it.
Two practical points:
- The asset still appears on the book balance sheet with normal MACRS depreciation. Section 179 / bonus depreciation creates a book-tax timing difference captured in deferred tax accounting. Don't let your tax-basis treatment overwrite the book ledger.
- The "placed in service" rule is strict. Equipment sitting in a crate in your storage room on December 31 doesn't qualify. It must be installed, calibrated, and ready for clinical use.
Manufacturer-Required Consumables
Most energy-based devices require proprietary treatment tips—CoolSculpting applicators, Morpheus8 tips, Vivace handpieces. These are perishable consumables sold to you on a per-treatment basis. Track them as inventory, relieve to COGS per use, and reconcile your consumable purchases against your treatment volume monthly. A mismatch (more tips than treatments) signals either lost inventory or unbilled treatments—both of which need attention.
The MSO/PC Structure and What It Means for Your Books
In most states with corporate practice of medicine ("CPOM") rules—California most aggressively, plus New York, Texas, New Jersey, and many others—the clinical entity must be a physician-owned Professional Corporation (PC) or Professional LLC. The non-physician business owner sets up a parallel Management Services Organization (MSO) that contracts with the PC to provide everything non-clinical: facility, equipment, marketing, billing, scheduling, HR, IT.
California's SB 351 (effective January 2026) further tightened CPOM enforcement, so the integrity of the MSO/PC split now matters even more.
What This Means for Your Chart of Accounts
You actually have two sets of books:
- The PC records: patient service revenue, clinical labor (physicians, nurses, PAs, NPs, aestheticians performing medical services), medical supplies COGS, professional liability insurance, medical-director fee paid out.
- The MSO records: management-services fee revenue from the PC, rent, equipment depreciation, marketing, admin staff, non-clinical IT, accounting.
The MSO charges the PC a management services fee that's typically a percentage of collections or a fixed monthly amount that compensates for fair value of services delivered. That fee is revenue to the MSO and expense to the PC. Most MSO/PC structures consolidate to a variable interest entity (VIE) for reporting purposes—but the underlying separate-entity books must stand on their own, with separate bank accounts, separate payroll, and arm's-length intercompany agreements.
The medical director, who must be a licensed physician actively engaged in clinical supervision in nearly every state, is typically paid by the PC—either as an owner-shareholder or under a fair-market-value medical director services agreement. The fee must reflect actual oversight hours; flat monthly retainers with no documented work invite both compliance scrutiny and IRS Section 162 reasonable-compensation challenges.
GLP-1 Weight Loss Programs: The New Profit Center
Compounded and branded GLP-1 medications (semaglutide, tirzepatide) have become the fastest-growing revenue line in many aesthetic practices. The accounting needs the same discipline as injectables—but with extra regulatory complexity.
After the FDA declared the semaglutide and tirzepatide shortages resolved in 2024 and early 2025, broad 503A compounding of name-brand copies became largely off-limits. What remains legal in 2026 is branded GLP-1 prescribing, 503B outsourcing-facility supply within scope, and 503A patient-specific compounding when documented clinical need exists. Each model produces different revenue and COGS profiles.
For bookkeeping:
- Inventory or pass-through? If the medication is dispensed in-house, it's inventory until administered. If it's prescribed and shipped directly to the patient by an external pharmacy, the clinic is providing a service (the consultation, the program management) and the medication is not on your balance sheet at all.
- Program revenue vs. medication revenue. Many clinics bundle the GLP-1 program: monthly fee covers visit, labs, the prescription, and ongoing coaching. Under ASC 606, identify the performance obligations and allocate the transaction price. If consultation and medication are distinct, you split revenue across the visit, the medication, and any included follow-up.
- Track the regulatory line. Keep separate revenue accounts for branded prescribing, 503B-supplied medication, and patient-specific compounding. State medical boards and the FDA increasingly examine medspas' weight-loss programs, and a clean revenue split shortens any audit response.
Tips, Gratuities, and the Section 45B FICA Tip Credit
Aestheticians, nurse injectors, and laser technicians often receive tips that pass through the clinic's POS. Tips are not revenue to the practice; they're a liability to the employee. The journal at receipt:
Dr. Cash $50
Cr. Tips Payable $50Disbursement to the employee clears the liability. Tips are wages subject to FICA—and Section 45B gives employers a credit against income tax for the employer-share FICA paid on tips that exceed federal minimum wage hours. For a busy injector earning $100,000+ a year in tips, the 45B credit is genuinely worth running through your tax return.
Form 8027 large-food-and-beverage reporting doesn't apply, but state-level tip-credit and tip-pooling rules do. Document your tip policy in writing, and reconcile POS tip totals to W-2 wages every quarter.
Reconciling MindBody, Vagaro, Aesthetic Record, and PatientNow
Most medspas live in their booking and EMR systems—MindBody, Vagaro, Aesthetic Record, Boulevard, PatientNow, Symplast, Nextech. These systems are the source of truth for patient transactions, but they are not the general ledger. Three integrations matter:
- Daily sales journal. Pull a daily sales summary from the EMR, post to the GL by revenue category. Reconcile total daily collections to the merchant processor deposit.
- Deferred revenue reconciliation. The EMR's "unredeemed package balance" report at month-end must match the Deferred Revenue liability balance in the GL. If they diverge, find out which way and why—almost always it's a package sold but not entered as deferred revenue, or a service rendered but not relieved from the liability.
- Inventory reconciliation. EMR-tracked inventory of injectables and consumables should match the GL inventory balance. A monthly physical count is essential for high-value items; pharmaceutical inventory shrinkage from theft, miscount, or expiration is a real risk.
Accurate bookkeeping from day one prevents tax headaches and valuation surprises later. The clinics that sell for the highest multiples are the ones whose financials a buyer can trust—clean revenue categories, properly deferred packages, consistent COGS, defensible MSO/PC documentation.
KPIs Lenders and Acquirers Actually Care About
When you raise capital or sell, the diligence team will compute these whether or not you do. Build them into your monthly close:
- Revenue per active patient (LTM)
- Gross margin by service line (injectables vs. laser vs. weight loss)
- Provider productivity: revenue per provider hour
- Inventory turnover for injectables (target: 8–12 turns per year)
- Deferred revenue as a percentage of trailing 12-month revenue (high deferred = healthy package sales; very high deferred = potential overhang of unredeemed obligations)
- Membership retention rate and average membership lifetime
- Patient retention (12-month repeat rate)
- Customer acquisition cost by channel vs. lifetime value
These KPIs come straight out of properly categorized accounting. If your books mix revenue lines, omit deferred revenue, or expense injectables at purchase, none of them are calculable.
Keep Your Aesthetic Practice Financially Audit-Ready
As you grow your medspa—adding service lines, hiring providers, opening new locations, or preparing for a strategic sale—maintaining clear, well-categorized financial records is essential. Beancount.io offers plain-text accounting that's transparent, version-controlled, and AI-ready, with Fava dashboards that give you the per-service-line margin visibility most off-the-shelf systems can't produce. Get started for free and see why operators in margin-sensitive service businesses are switching to plain-text accounting.